Icad Inc (ICAD) 10.68 $ICAD
iCAD to Host First Quarter 2015 Financial Results Conference Call on Thursday, April 30, 2015
GlobeNewswire - Thu Apr 16, 3:05PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the first quarter ended March 31, 2015 before market open on Thursday, April 30, 2015.
ICAD: 10.68 (+0.82)
Positive Clinical Data for iCAD's Xoft System to be Highlighted at American Brachytherapy Society (ABS) Annual Meeting
PR Newswire - Tue Apr 07, 7:00AM CDT
Booth # 107 -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced first-year data from the company's ExBRT ("A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer"
trial evaluating the Xoft System for the treatment of early stage breast cancer will be presented at the American Brachytherapy Society (ABS) Annual Meeting, April 9-11, in Orlando, FL. In addition, data for the treatment of non-melanoma skin cancer (NMSC) will be presented. The Xoft System's suite of products and services for clinical practices will be showcased at the Xoft booth (#107) throughout the meeting.
ICAD: 10.68 (+0.82)
Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: CAD Use Rises despite Controversies
M2 - Thu Mar 26, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x45l84/computer_aided) has announced the addition of the "Computer Aided Detection (CAD) - Global Strategic Business Report" report to their offering. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the US and European markets for Computer Aided Detection (CAD) in US$ Thousands by the following Application Segments - Breast, Chest, and Others. The US market is also analysed in Number of Units for the above Application Segments. The report also provides a consolidated, single-segment volume analysis for the European market. The report profiles 29 companies including many key and niche players such as: - EDDA Technology, Inc. (US) - Hologic, Inc. (US) - iCAD, Inc. (US) - Invivo Corp. (US) - Merge Healthcare, Inc. (US) - Riverain Technologies (US) - Salient Imaging, Inc. (US) - Siemens Healthcare (Germany) - VuCOMP Inc. (US) Key Topics Covered: 1. OUTLOOK 2. MARKET OVERVIEW & TRENDS 3. COMPETITION 4. APPLICATIONS OF CAD 5. REGIONAL PERSPECTIVE 6. PRODUCT OVERVIEW 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS III. COMPETITIVE LANDSCAPE - Total Companies Profiled: 29 (including Divisions/Subsidiaries - 31) - The United States (21) - Japan (1) - Europe (
- - Germany (2) - - Italy (1) - - Spain (1) - - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/x4...uter_aided
ICAD: 10.68 (+0.82), MRGE: 5.57 (+0.06), HOLX: 33.26 (-0.07)
iCAD To Present Positive Four-Year Data On Xoft® Axxent® Electronic Brachytherapy (eBx®) System® For Non-Melanoma Skin Cancer (NMSC)
PR Newswire - Fri Mar 20, 10:38AM CDT
(Booth # 5151) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present three E-posters highlighting results of up to four years of follow up with the Xoft Axxent® Electronic Brachytherapy (eBx®) System® in the treatment of non-melanoma skin cancer (NMSC) at The American Academy of Dermatology 73rd Annual Meeting in San Francisco, California. The Xoft System's suite of products and services for clinical practices will also be showcased at the Xoft booth (#5151) throughout the meeting from March 20-24.
ICAD: 10.68 (+0.82)
iCAD to Present at the 27th Annual ROTH Conference
GlobeNewswire - Mon Mar 02, 3:05PM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Ken Ferry, Chief Executive Officer, will present at the 27 Annual ROTH Conference at The Ritz Carlton in Dana Point, CA.
ICAD: 10.68 (+0.82)
iCAD (ICAD) CEO Ken Ferry on Q4 2014 Results - Earnings Calls Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 9:21PM CST
ICAD: 10.68 (+0.82)
iCAD (ICAD) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 24, 3:55PM CST
ICAD: 10.68 (+0.82)
iCAD reports Q4 earnings
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:49PM CST
ICAD: 10.68 (+0.82)
iCAD to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Fri Feb 13, 7:30AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Tuesday, February 24, 2015.
ICAD: 10.68 (+0.82)
15.2% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Fri Jan 30, 9:32AM CST
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on December 11th, 2014 at $9.37. In approximately 2 months, Icad has returned 15.15% as of today's recent price of $7.95.
ICAD: 10.68 (+0.82)
iCAD Announces More Than 500 Patients Treated In Study Of Intraoperative Radiation Therapy (IORT) For Early-Stage Breast Cancer
PR Newswire - Wed Dec 10, 4:02PM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today that more than 500 patients have been treated in its clinical trial of intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The study, "A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer (the ExBRT study)," compares the Xoft System to traditional external beam radiation therapy (EBRT). Patients in the study were treated with a targeted, single-fraction dose of radiation using the Xoft System at the time of lumpectomy.
ICAD: 10.68 (+0.82)
iCAD to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on Tuesday, December 2, 2014
Business Wire - Wed Nov 26, 7:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Ken Ferry, President and CEO of iCAD, Inc., will present a corporate overview on Tuesday, December 2, 2014 at 12:30 p.m. PST (3:30 p.m. EST).
ICAD: 10.68 (+0.82)
iCAD Showcases Advanced Mammography and Computed Tomography Colonography (CTC) CAD Solutions at Radiological Society of North America 2014 Annual Meeting
PR Newswire - Tue Nov 25, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will feature advanced computer-aided detection (CAD) solutions for the early detection of breast and colon cancers during the 100th Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 - Dec. 5. Symposia, posters, and workshops discuss the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD's 2D mammography, tomosynthesis, and Computed Tomography Colonography (CTC) CAD and workflow technologies will be featured at booth #4135 in Hall A.
ICAD: 10.68 (+0.82)
iCAD raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:46AM CDT
ICAD: 10.68 (+0.82)
iCAD, Inc. beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
ICAD: 10.68 (+0.82)
iCAD Reports Third Quarter Financial Results
Business Wire - Tue Oct 28, 3:06PM CDT
--Increases Financial Guidance for 2014
ICAD: 10.68 (+0.82)
iCAD to Host Third Quarter 2014 Financial Results Conference Call on Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 7:30AM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and nine months ended September 30, 2014 following the close of the market on Tuesday, October 28, 2014.
ICAD: 10.68 (+0.82)
Icad Shares Up 36.0% Since SmarTrend's Buy Recommendation (ICAD)
Comtex SmarTrend(R) - Thu Sep 25, 9:11AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 35.98% as of today's recent price of $9.94.
ICAD: 10.68 (+0.82)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into iCAD Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu Sep 18, 4:15PM CDT
Levi & Korsinsky, LLP is investigating iCAD Inc. (Nasdaq: ICAD) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
ICAD: 10.68 (+0.82)
iCAD to Host First Quarter 2015 Financial Results Conference Call on Thursday, April 30, 2015
GlobeNewswire - Thu Apr 16, 3:05PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the first quarter ended March 31, 2015 before market open on Thursday, April 30, 2015.
ICAD: 10.68 (+0.82)
Positive Clinical Data for iCAD's Xoft System to be Highlighted at American Brachytherapy Society (ABS) Annual Meeting
PR Newswire - Tue Apr 07, 7:00AM CDT
Booth # 107 -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced first-year data from the company's ExBRT ("A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer"
trial evaluating the Xoft System for the treatment of early stage breast cancer will be presented at the American Brachytherapy Society (ABS) Annual Meeting, April 9-11, in Orlando, FL. In addition, data for the treatment of non-melanoma skin cancer (NMSC) will be presented. The Xoft System's suite of products and services for clinical practices will be showcased at the Xoft booth (#107) throughout the meeting. ICAD: 10.68 (+0.82)
Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: CAD Use Rises despite Controversies
M2 - Thu Mar 26, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x45l84/computer_aided) has announced the addition of the "Computer Aided Detection (CAD) - Global Strategic Business Report" report to their offering. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the US and European markets for Computer Aided Detection (CAD) in US$ Thousands by the following Application Segments - Breast, Chest, and Others. The US market is also analysed in Number of Units for the above Application Segments. The report also provides a consolidated, single-segment volume analysis for the European market. The report profiles 29 companies including many key and niche players such as: - EDDA Technology, Inc. (US) - Hologic, Inc. (US) - iCAD, Inc. (US) - Invivo Corp. (US) - Merge Healthcare, Inc. (US) - Riverain Technologies (US) - Salient Imaging, Inc. (US) - Siemens Healthcare (Germany) - VuCOMP Inc. (US) Key Topics Covered: 1. OUTLOOK 2. MARKET OVERVIEW & TRENDS 3. COMPETITION 4. APPLICATIONS OF CAD 5. REGIONAL PERSPECTIVE 6. PRODUCT OVERVIEW 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS III. COMPETITIVE LANDSCAPE - Total Companies Profiled: 29 (including Divisions/Subsidiaries - 31) - The United States (21) - Japan (1) - Europe (
- - Germany (2) - - Italy (1) - - Spain (1) - - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/x4...uter_aided ICAD: 10.68 (+0.82), MRGE: 5.57 (+0.06), HOLX: 33.26 (-0.07)
iCAD To Present Positive Four-Year Data On Xoft® Axxent® Electronic Brachytherapy (eBx®) System® For Non-Melanoma Skin Cancer (NMSC)
PR Newswire - Fri Mar 20, 10:38AM CDT
(Booth # 5151) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present three E-posters highlighting results of up to four years of follow up with the Xoft Axxent® Electronic Brachytherapy (eBx®) System® in the treatment of non-melanoma skin cancer (NMSC) at The American Academy of Dermatology 73rd Annual Meeting in San Francisco, California. The Xoft System's suite of products and services for clinical practices will also be showcased at the Xoft booth (#5151) throughout the meeting from March 20-24.
ICAD: 10.68 (+0.82)
iCAD to Present at the 27th Annual ROTH Conference
GlobeNewswire - Mon Mar 02, 3:05PM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Ken Ferry, Chief Executive Officer, will present at the 27 Annual ROTH Conference at The Ritz Carlton in Dana Point, CA.
ICAD: 10.68 (+0.82)
iCAD (ICAD) CEO Ken Ferry on Q4 2014 Results - Earnings Calls Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 9:21PM CST
ICAD: 10.68 (+0.82)
iCAD (ICAD) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 24, 3:55PM CST
ICAD: 10.68 (+0.82)
iCAD reports Q4 earnings
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:49PM CST
ICAD: 10.68 (+0.82)
iCAD to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Fri Feb 13, 7:30AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Tuesday, February 24, 2015.
ICAD: 10.68 (+0.82)
15.2% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Fri Jan 30, 9:32AM CST
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on December 11th, 2014 at $9.37. In approximately 2 months, Icad has returned 15.15% as of today's recent price of $7.95.
ICAD: 10.68 (+0.82)
iCAD Announces More Than 500 Patients Treated In Study Of Intraoperative Radiation Therapy (IORT) For Early-Stage Breast Cancer
PR Newswire - Wed Dec 10, 4:02PM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today that more than 500 patients have been treated in its clinical trial of intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The study, "A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer (the ExBRT study)," compares the Xoft System to traditional external beam radiation therapy (EBRT). Patients in the study were treated with a targeted, single-fraction dose of radiation using the Xoft System at the time of lumpectomy.
ICAD: 10.68 (+0.82)
iCAD to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on Tuesday, December 2, 2014
Business Wire - Wed Nov 26, 7:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Ken Ferry, President and CEO of iCAD, Inc., will present a corporate overview on Tuesday, December 2, 2014 at 12:30 p.m. PST (3:30 p.m. EST).
ICAD: 10.68 (+0.82)
iCAD Showcases Advanced Mammography and Computed Tomography Colonography (CTC) CAD Solutions at Radiological Society of North America 2014 Annual Meeting
PR Newswire - Tue Nov 25, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will feature advanced computer-aided detection (CAD) solutions for the early detection of breast and colon cancers during the 100th Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 - Dec. 5. Symposia, posters, and workshops discuss the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD's 2D mammography, tomosynthesis, and Computed Tomography Colonography (CTC) CAD and workflow technologies will be featured at booth #4135 in Hall A.
ICAD: 10.68 (+0.82)
iCAD raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:46AM CDT
ICAD: 10.68 (+0.82)
iCAD, Inc. beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
ICAD: 10.68 (+0.82)
iCAD Reports Third Quarter Financial Results
Business Wire - Tue Oct 28, 3:06PM CDT
--Increases Financial Guidance for 2014
ICAD: 10.68 (+0.82)
iCAD to Host Third Quarter 2014 Financial Results Conference Call on Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 7:30AM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and nine months ended September 30, 2014 following the close of the market on Tuesday, October 28, 2014.
ICAD: 10.68 (+0.82)
Icad Shares Up 36.0% Since SmarTrend's Buy Recommendation (ICAD)
Comtex SmarTrend(R) - Thu Sep 25, 9:11AM CDT
SmarTrend identified an Uptrend for Icad (NASDAQ:ICAD) on July 14th, 2014 at $7.31. In approximately 2 months, Icad has returned 35.98% as of today's recent price of $9.94.
ICAD: 10.68 (+0.82)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into iCAD Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu Sep 18, 4:15PM CDT
Levi & Korsinsky, LLP is investigating iCAD Inc. (Nasdaq: ICAD) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
ICAD: 10.68 (+0.82)
